ClinicalTrials.gg
CompletedNCT01211405Updated Jun 5, 2025Results posted

Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder

A Phase 2 interventional study of Low dose MDMA-assisted therapy and Medium dose MDMA-assisted therapy in Posttraumatic Stress Disorder, sponsored by Lykos Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-05.

Sponsored by Lykos Therapeutics (part of Resilient Pharmaceuticals) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic — 11 open to participants now, 12 under way, 1 of them phase 3. N-Methyl-3,4-methylenedioxyamphetamine · Stress Disorders, Post-Traumatic.

Enrollment
18th of 38
26 · median 25
Started
2010
with 1 other
Phase 2
28 of 38
10 open now
Registered
4th of 38
by date
Lead sponsor
16 of 38
Lykos Therapeutics

Among the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, this one is the 18th largest by enrollment, is one of 2 that started in 2010, is one of 28 in phase 2, and was the 4th registered.

Stress Disorders, Post-Traumatic

2,688 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 606 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

11 of the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic are open now, in 3 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About N-Methyl-3,4-methylenedioxyamphetamine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective and reducing PTSD symptoms in veterans with chronic PTSD. The main question it aims to answer is: Do three doses of MDMA reduce PTSD symptoms?

Researchers will compare 30, 75, and 125 mg of MDMA HCl with therapy to see which dose best reduces PTSD symptoms.

Participants will undergo three preparatory non-drug therapy sessions with a male and female co-therapist team, then undergo three day-long MDMA-assisted therapy sessions after receiving an initial dose of 30, 75, or 125 mg MDMA HCl. After each MDMA-assisted therapy session, participants will undergo three integrative therapy sessions.

Read the detailed description

This study is a randomized, double-blind, dose comparison study with an open-label cross-over segment that will assess the safety and efficacy of MDMA-assisted therapy in veterans with chronic PTSD. Twelve of 24 participants will receive the full dose of 125 mg, six will receive 75 mg and six will receive 30 mg (active placebo dose) of MDMA HCl. An independent rater blind to condition will assess symptoms of PTSD and depression, general quality of life and posttraumatic growth prior to any therapy sessions one month after the second experimental session.

After undergoing three 90-minute non-drug introductory therapy sessions with a male/female co-therapist team, study participants will undergo two eight-hour long experimental sessions scheduled three to five weeks apart, prior to which they will be randomized to receive an initial dose of 30, 75 or 125 mg MDMA HCl , followed by a supplemental dose of half the initial dose 1.5 to 2.5 hours later. Participants will undergo integrative therapy in between each experimental session, including on the day after each session. Vital signs and psychological distress will be measured throughout each experimental session, and suicidality will be assessed throughout the course of the study. Spontaneously reported side effects will be collected on the day of each experimental session, and for six days afterward. PTSD symptoms, symptoms of depression, general psychological function, posttraumatic growth and quality of sleep will be assessed one month after the second experimental session, and the blind will be broken.

Participants who received 125 mg MDMA HCl will continue to have a third experimental session, and they will be assessed two months after the third experimental session.

Participants who received 30 or 75 mg MDMA HCl may take part in an open-label crossover segment that will follow nearly identical procedures, except that there will only be one introductory session prior to the first experimental session. There will be three experimental sessions. Symptoms of PTSD, depression and posttraumatic growth will be assessed at the start of the study. They will also be assessed one month after the second and two months after the third experimental session.

All participants will be assessed 12 months after their final experimental session. PTSD and depression symptoms and posttraumatic growth will be assessed, and participants will complete a questionnaire concerning the costs and benefits of being in the study.

03

Conditions studied

  • Posttraumatic Stress Disorder

Keywords

  • MDMA
  • Therapy
  • Veterans
  • Posttraumatic Stress Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be diagnosed with chronic PTSD, duration of 6 months or longer resulting from traumatic experience during military service;
  • Have a CAPS score showing moderate to severe PTSD symptoms;
  • Have had at least one unsuccessful attempt at treatment for PTSD either with talk therapy or with drugs, or discontinuing treatment because of inability to tolerate psychotherapy or drug therapy.
  • Are at least 18 years old;
  • Must be generally healthy;
  • Must sign a medical release for the investigators to communicate directly with their therapist and doctors;
  • Are willing to refrain from taking any psychiatric medications during the study period;
  • Willing to follow restrictions and guidelines concerning consumption of food, beverages, and nicotine the night before and just prior to each experimental session;
  • Willing to remain overnight at the study site;
  • Agree to have transportation other than driving themselves home or to where they are staying after the integrative session on the day after the MDMA session;
  • Are willing to be contacted via telephone for all necessary telephone contacts;
  • Must have a negative pregnancy test if able to bear children, and agree to use an effective form of ;
  • Must provide a contact in the event of a participant becoming suicidal;
  • Are proficient in speaking and reading English;
  • Agree to have all clinic visit sessions recorded to audio and video
  • Agree not to participate in any other interventional clinical trials during the duration of this study.

Exclusion criteria

Exclusion Criteria:

  • Are pregnant or nursing, or if a woman who can have children, those who are not practicing an effective means of ;
  • Weigh less than 48 kg;
  • Are abusing illegal drugs;
  • Have used ecstasy (material representing itself as MDMA) more than 5 times or at least once in the last 6 months;
  • Are unable to give adequate ;
  • Upon review of past and current drugs/medication must not be on or have taken a medication that is exclusionary;
  • Upon review of medical or psychiatric history must not have any current or past diagnosis that would be considered a risk to participation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
26 participants (actual)

Study arms

  • Active comparator
    Low dose MDMA-assisted therapy

    Participants will receive 30 mg midomafetamine HCl (MDMA) with therapy during each of two blinded experimental sessions.

    Drug: Low dose MDMA-assisted therapy · Behavioral: Therapy

  • Active comparator
    Medium dose MDMA-assisted therapy

    Participants will receive 75 mg midomafetamine HCl (MDMA) with therapy on each of two blinded experimental sessions.

    Drug: Medium dose MDMA-assisted therapy · Behavioral: Therapy

  • Experimental
    Full dose MDMA-assisted therapy

    Participants will receive 125 mg midomafetamine HCl (MDMA) with therapy during each of two blinded experimental sessions, followed by a third open label session.

    Drug: Full dose MDMA-assisted therapy · Behavioral: Therapy

Interventions

  • 30 mg midomafetamine HCl administered p.o. once at start of an experimental session. Upon mutual agreement, this may be followed by a supplemental dose of 15 mg 1.5 to 2 hours later

    Also known as: MDMA, 3,4-methylenedioxymethamphetamine, midomafetamine

  • 75 mg midomafetamine HCl administered p.o. once at start of an experimental session. Upon mutual agreement, this may be followed by a supplemental dose of 37.5 mg 1.5 to 2 hours later

    Also known as: MDMA, 3,4-methylenedioxymethamphetamine, midomafetamine

  • 125 mg midomafetamine HCl administered p.o. once at start of an experimental session. Upon mutual agreement, this may be followed by a supplemental dose of 62.5 mg 1.5 to 2 hours later

    Also known as: MDMA, 3,4-methylenedioxymethamphetamine, midomafetamine

  • BehavioralTherapy

    Non-directive therapy during each session

06

What researchers measure

Primary outcomes

  1. Change in Clinician-Administered PTSD Scale (CAPS-IV) From Baseline to Primary Endpoint

    The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

    Time frame: Baseline to one month after second experimental session

Secondary outcomes

  1. Change in Global Assessment of Function (GAF) From Baseline to Primary Endpoint

    The Global Assessment of Functioning (GAF) Scale is a numeric scale ranging from 0 through 100 that is used by mental health clinicians and physicians to subjectively rate the social, occupational, and psychological functioning of adults. Higher scores indicate better functioning.

    Time frame: Baseline to one month after second experimental session

  2. Change in Posttraumatic Growth Inventory (PTGI) From Baseline to Primary Endpoint

    The Posttraumatic Growth Inventory (PTGI) is a 21-item self-report measure of perceived growth or benefits occurring after a traumatic event. It contains five subscales; relationship to others, new possibilities, personal strength, spiritual change, and appreciation of life. Questions are answered on a scale from 0 (I did not experience this change) to 5 (I experienced this change to a great degree). Items are added to calculate the total PTGI score which ranges from 0 to 105, with higher scores indicative of greater growth.

    Time frame: Baseline to one month after second experimental session

  3. Change in Beck Depression Inventory (BDI-II) From Baseline to Primary Endpoint

    Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The BDI-II is scored by summing the ratings for the 21 items. Each item is rated on a 4-point scale ranging from 0 to 3. The maximum total score is 63.

    Time frame: Baseline to one month after second experimental session

  4. Change in Dissociative Experience Scale (DES-II) From Baseline to Primary Endpoint

    The DES-II is a 28-item self-report measure of dissociation, defined as a lack of normal integration of an individual's thoughts, feelings, or experiences into the stream of consciousness or memory. Respondents indicate how often the specific experience happens to them, from "never" (0% of the time) to "always" (100%). The scale is scored by treating percentages as single digits and summing to produce a total score, ranging from 0 to 100. The higher the score, the more dissociative symptoms.

    Time frame: Baseline to one month after second experimental session

  5. Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline to Primary Endpoint

    The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 18 items that yield seven component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality.

    Time frame: Baseline to one month after second experimental session

07

Results

Posted Feb 2, 2022

Participant flow

Participant flow — Overall Study
MilestoneLow Dose MDMA (30 mg)Medium Dose MDMA (75 mg)Full Dose MDMA (125 mg)
Started7712
Completed primary endpoint7712
Completed stage 16612
Completed stage 2660
Completed6711
Not completed101

Outcome measures

PrimaryChange in Clinician-Administered PTSD Scale (CAPS-IV) From Baseline to Primary Endpoint

The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

Time frame:
Baseline to one month after second experimental session
Reported as:
Mean · score on a scale
Change in Clinician-Administered PTSD Scale (CAPS-IV) From Baseline to Primary Endpoint
score on a scaleLow Dose MDMA (30 mg)Medium Dose MDMA (75 mg)Full Dose MDMA (125 mg)
Change in Clinician-Administered PTSD Scale (CAPS-IV) From Baseline to Primary Endpoint-11.4 ± 12.7-58.3 ± 9.8-44.3 ± 28.7
SecondaryChange in Global Assessment of Function (GAF) From Baseline to Primary Endpoint

The Global Assessment of Functioning (GAF) Scale is a numeric scale ranging from 0 through 100 that is used by mental health clinicians and physicians to subjectively rate the social, occupational, and psychological functioning of adults. Higher scores indicate better functioning.

Time frame:
Baseline to one month after second experimental session
Reported as:
Mean · score on a scale
Change in Global Assessment of Function (GAF) From Baseline to Primary Endpoint
score on a scaleLow Dose MDMA (30 mg)Medium Dose MDMA (75 mg)Full Dose MDMA (125 mg)
Change in Global Assessment of Function (GAF) From Baseline to Primary Endpoint1.1 ± 4.619.4 ± 6.118.4 ± 14.4
SecondaryChange in Posttraumatic Growth Inventory (PTGI) From Baseline to Primary Endpoint

The Posttraumatic Growth Inventory (PTGI) is a 21-item self-report measure of perceived growth or benefits occurring after a traumatic event. It contains five subscales; relationship to others, new possibilities, personal strength, spiritual change, and appreciation of life. Questions are answered on a scale from 0 (I did not experience this change) to 5 (I experienced this change to a great degree). Items are added to calculate the total PTGI score which ranges from 0 to 105, with higher scores indicative of greater growth.

Time frame:
Baseline to one month after second experimental session
Reported as:
Mean · score on a scale
Change in Posttraumatic Growth Inventory (PTGI) From Baseline to Primary Endpoint
score on a scaleLow Dose MDMA (30 mg)Medium Dose MDMA (75 mg)Full Dose MDMA (125 mg)
Change in Posttraumatic Growth Inventory (PTGI) From Baseline to Primary Endpoint-11.6 ± 12.236.1 ± 12.033.7 ± 24.0
SecondaryChange in Beck Depression Inventory (BDI-II) From Baseline to Primary Endpoint

Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The BDI-II is scored by summing the ratings for the 21 items. Each item is rated on a 4-point scale ranging from 0 to 3. The maximum total score is 63.

Time frame:
Baseline to one month after second experimental session
Reported as:
Mean · score on a scale
Change in Beck Depression Inventory (BDI-II) From Baseline to Primary Endpoint
score on a scaleLow Dose MDMA (30 mg)Medium Dose MDMA (75 mg)Full Dose MDMA (125 mg)
Change in Beck Depression Inventory (BDI-II) From Baseline to Primary Endpoint-4.6 ± 8.8-15.4 ± 9.5-24.6 ± 10.6
SecondaryChange in Dissociative Experience Scale (DES-II) From Baseline to Primary Endpoint

The DES-II is a 28-item self-report measure of dissociation, defined as a lack of normal integration of an individual's thoughts, feelings, or experiences into the stream of consciousness or memory. Respondents indicate how often the specific experience happens to them, from "never" (0% of the time) to "always" (100%). The scale is scored by treating percentages as single digits and summing to produce a total score, ranging from 0 to 100. The higher the score, the more dissociative symptoms.

Time frame:
Baseline to one month after second experimental session
Reported as:
Mean · score on a scale
Change in Dissociative Experience Scale (DES-II) From Baseline to Primary Endpoint
score on a scaleLow Dose MDMA (30 mg)Medium Dose MDMA (75 mg)Full Dose MDMA (125 mg)
Change in Dissociative Experience Scale (DES-II) From Baseline to Primary Endpoint1.8 ± 0.95-8.6 ± 1.9-8.8 ± 6.2
SecondaryChange in Pittsburgh Sleep Quality Index (PSQI) From Baseline to Primary Endpoint

The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 18 items that yield seven component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality.

Time frame:
Baseline to one month after second experimental session
Reported as:
Mean · score on a scale
Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline to Primary Endpoint
score on a scaleLow Dose MDMA (30 mg)Medium Dose MDMA (75 mg)Full Dose MDMA (125 mg)
Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline to Primary Endpoint1.8 ± 2.8-6.4 ± 7.1-4.8 ± 4.1

Adverse events

Collected over During entire study duration (approx 12 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Blinded Low Dose MDMA-assisted Therapy0/7 (0%)1/7 (14.3%)6/7 (85.7%)
Blinded Medium Dose MDMA-assisted Therapy0/7 (0%)0/7 (0%)4/7 (57.1%)
Blinded Full Dose MDMA-assisted Therapy0/12 (0%)0/12 (0%)8/12 (66.7%)
Open-Label Low Dose MDMA-assisted Therapy0/6 (0%)1/6 (16.7%)6/6 (100%)
Open-Label Medium Dose MDMA-assisted Therapy0/6 (0%)0/6 (0%)4/6 (66.7%)
Open-Label Full Dose MDMA-assisted Therapy0/12 (0%)0/12 (0%)4/12 (33.3%)
Low Dose Group 12 Month Follow-Up0/6 (0%)1/6 (16.7%)0/6 (0%)
Medium Dose Group 12 Month Follow-Up0/7 (0%)1/7 (14.3%)0/7 (0%)
Full Dose Group 12 Month Follow-Up0/11 (0%)0/11 (0%)0/11 (0%)
SRRS: Low Dose0/7 (0%)0/7 (0%)7/7 (100%)
SRRs: Medium Dose0/7 (0%)0/7 (0%)7/7 (100%)
SRRs: Full Dose0/12 (0%)0/12 (0%)12/12 (100%)
Most frequent serious events
Most frequent serious events
EventBlinded Low Dose MDMA-assisted TherapyBlinded Medium Dose MDMA-assisted TherapyBlinded Full Dose MDMA-assisted TherapyOpen-Label Low Dose MDMA-assisted TherapyOpen-Label Medium Dose MDMA-assisted TherapyOpen-Label Full Dose MDMA-assisted TherapyLow Dose Group 12 Month Follow-UpMedium Dose Group 12 Month Follow-UpFull Dose Group 12 Month Follow-UpSRRS: Low DoseSRRs: Medium DoseSRRs: Full Dose
Major DepressionPsychiatric disorders0/70/70/120/60/60/121/60/70/11———
Ventricular extrasystolesCardiac disorders0/70/70/121/60/60/120/60/70/11———
Suicidal IdeationPsychiatric disorders1/70/70/120/60/60/120/60/70/11———
AppendicitisInfections and infestations0/70/70/120/60/60/120/61/70/11———
Most frequent other events
Showing 10 of 72
Most frequent other events
EventBlinded Low Dose MDMA-assisted TherapyBlinded Medium Dose MDMA-assisted TherapyBlinded Full Dose MDMA-assisted TherapyOpen-Label Low Dose MDMA-assisted TherapyOpen-Label Medium Dose MDMA-assisted TherapyOpen-Label Full Dose MDMA-assisted TherapyLow Dose Group 12 Month Follow-UpMedium Dose Group 12 Month Follow-UpFull Dose Group 12 Month Follow-UpSRRS: Low DoseSRRs: Medium DoseSRRs: Full Dose
FatigueGeneral disorders2/70/70/120/60/60/120/60/70/116/77/710/12
Need More SleepGeneral disorders0/70/70/120/60/60/120/60/70/116/76/79/12
AnxietyNervous system disorders1/70/71/122/60/60/120/60/70/114/75/710/12
InsomniaNervous system disorders0/70/71/120/60/61/120/60/70/115/73/710/12
HeadacheGeneral disorders0/70/70/120/60/60/120/60/70/112/73/77/12
Muscle TensionGeneral disorders0/70/70/120/60/60/120/60/70/112/73/77/12
Increased IrritabilityGeneral disorders0/70/70/120/60/60/120/60/70/114/72/76/12
Sleep deficitNervous system disorders1/70/70/123/60/60/120/60/70/110/70/70/12
Lack of AppetiteGeneral disorders0/70/70/120/60/60/120/60/70/112/71/76/12
Low MoodGeneral disorders0/70/70/120/60/60/120/60/70/113/70/73/12

Baseline characteristics

Intent-to-treat

Age, Continuous
Age, Continuous(years)Low Dose MDMA (30 mg)Medium Dose MDMA (75 mg)Full Dose MDMA (125 mg)Total
Mean39.2 ± 9.729.1 ± 4.040.7 ± 11.137.2 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)Low Dose MDMA (30 mg)Medium Dose MDMA (75 mg)Full Dose MDMA (125 mg)Total
Female2147
Male56819
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Low Dose MDMA (30 mg)Medium Dose MDMA (75 mg)Full Dose MDMA (125 mg)Total
Ethnicity — White/Caucasian641222
Ethnicity — Latino/Hispanic1102
Ethnicity — Native American0101
Ethnicity — Other0101
08

Study locations

1 site
  • Offices of Michael Mithoefer
    Mount Pleasant, South Carolina 29464-4345, United States
09

References and documents

Publications

  • Mithoefer MC, Mithoefer AT, Feduccia AA, Jerome L, Wagner M, Wymer J, Holland J, Hamilton S, Yazar-Klosinski B, Emerson A, Doblin R. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry. 2018 Jun;5(6):486-497. doi: 10.1016/S2215-0366(18)30135-4. Epub 2018 May 1. PubMed 29728331 ↗
  • Jerome L, Feduccia AA, Wang JB, Hamilton S, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology (Berl). 2020 Aug;237(8):2485-2497. doi: 10.1007/s00213-020-05548-2. Epub 2020 Jun 4. PubMed 32500209 ↗
  • Feduccia AA, Jerome L, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline. Front Psychiatry. 2019 Sep 12;10:650. doi: 10.3389/fpsyt.2019.00650. eCollection 2019. PubMed 31572236 ↗
  • Mithoefer MC, Feduccia AA, Jerome L, Mithoefer A, Wagner M, Walsh Z, Hamilton S, Yazar-Klosinski B, Emerson A, Doblin R. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology (Berl). 2019 Sep;236(9):2735-2745. doi: 10.1007/s00213-019-05249-5. Epub 2019 May 7. PubMed 31065731 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — We will share de-identified outcome data appearing in any published reports upon request. IPD may include de-identified baseline, demographic and outcome measure data. To ensure participant privacy, it will never include PHI. Please contact the central trial contact for details about data sharing and data available.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data and study-related documents will be available following primary publication of outcomes.

Access criteria: Interested persons should correspond with the central contact for the study.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2010 to primary completion in Jun 2015, 54 months.

Results were first posted in Feb 2022, 6 years 7 months after primary completion. A results delay was requested in Mar 2017.

Of 31 industry-sponsored phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 54 months is above that.

Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2010
First posted
Sep 29, 2010
StartActual
Nov 10, 2010
Primary completionActual
Jun 4, 2015
CompletionActual
Aug 2, 2016
Results delay requested
Mar 24, 2017
Results first posted
Feb 2, 2022
Last update
Jun 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01211405
Lead sponsor
Lykos Therapeutics
Responsible party
Sponsor
First posted
Sep 29, 2010
Start date
Nov 10, 2010
Primary completion
Jun 4, 2015
Completion
Aug 2, 2016
Results posted
Feb 2, 2022
Last update
Jun 5, 2025

Study contacts

Michael Mithoefer, MD
principal investigator · Private Practice
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine

Start the discussion